AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aon (AON) fell 1.11% on August 25, with a trading volume of $0.32 billion, a 27.78% decline from the previous day, ranking 277th in market activity. Institutional investors increased stakes in the financial services provider, including
Corp, which boosted its holdings by 15.7% in the first quarter to 6,856 shares valued at $2.74 million. Haverford Trust Co also raised its position by 13.7%, acquiring 46,531 additional shares to hold 386,749 shares worth $154.3 million.Analyst ratings showed mixed signals, with
Fitzgerald upgrading to "strong-buy" and moving to "buy" in recent months. The stock maintains an average "Moderate Buy" rating and a consensus price target of $409.18. reported quarterly earnings of $3.49 per share, exceeding estimates by $0.09, and declared a $0.745 per share dividend, yielding 0.8% annually. The company’s 10.5% year-over-year revenue growth and 50.91% return on equity highlight its operational strength.Institutional ownership now accounts for 86.14% of Aon’s shares, with hedge funds and large investors adjusting positions in Q1. The firm’s financial metrics include a market cap of $80.75 billion, a P/E ratio of 31.36, and a beta of 0.83, reflecting its defensive positioning. Despite recent upgrades, the stock remains near its 52-week low of $323.73, suggesting mixed investor sentiment amid broader market volatility.
The strategy of buying the top 500 stocks by daily trading volume and holding them for one day generated a total profit of $2,940 between December 2021 and August 2025. The maximum drawdown was -$1,960 during the same period, with a Sharpe ratio of 1.53 indicating strong risk-adjusted returns. The best monthly performance was $840 in December 2021, while the worst was -$790 in August 2025.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Dec.26 2025

Dec.26 2025

Dec.25 2025

Dec.24 2025

Dec.24 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet